Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Literature DB >> 8781117

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

B Gaugler¹, N Brouwenstijn, V Vantomme, J P Szikora, C W Van der Spek, J J Patard, T Boon, P Schrier, B J Van den Eynde.

Abstract

Previous reports have described antigens that are recognized on human melanoma cells by autologous cytolytic T lymphocytes (CTL). The genes coding for a number of these antigens have been identified. Here we report the cloning of a gene that codes for an antigen recognized by autologous CTL on a human renal carcinoma cell line. This antigen is presented by HLA-B7 and is encoded by a new gene that we have named RAGE1. No expression of RAGE1 was found in normal tissues other than retina. RAGE1 expression was found in only one of 57 renal cell carcinoma samples, and also in some sarcomas, infiltrating bladder carcinomas, and melanomas. This represents the first identification of an antigen recognized by autologous CTL on a renal tumor.

Entities: CellLine Disease Gene Species

Mesh：

Substances：

Year: 1996 PMID： 8781117 DOI： 10.1007/bf02602776

Source DB: PubMed Journal: Immunogenetics ISSN： 0093-7711 Impact factor: 2.846

41 in total

1. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors: P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal: Proc Natl Acad Sci U S A Date: 1995-08-15 Impact factor: 11.205

2. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors: C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal: Arch Surg Date: 1990-02

3. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal: Science Date: 1991-12-13 Impact factor: 47.728

4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors: S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal: JAMA Date: 1994 Mar 23-30 Impact factor: 56.272

5. Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors: M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal: Int J Cancer Date: 1987-03-15 Impact factor: 7.396

Review 6. Tumor antigens recognized by T lymphocytes.

Authors: T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal: Annu Rev Immunol Date: 1994 Impact factor: 28.527

7. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors: A Belldegrun; L M Muul; S A Rosenberg
Journal: Cancer Res Date: 1988-01-01 Impact factor: 12.701

8. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors: T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal: Science Date: 1995-09-01 Impact factor: 47.728

9. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors: P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal: J Exp Med Date: 1994-07-01 Impact factor: 14.307

10. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors: T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal: J Exp Med Date: 1980-11-01 Impact factor: 14.307

30 in total

Review 1. T cell receptor usage in malignant diseases.

Authors: E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal: Springer Semin Immunopathol Date: 1999

2. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Authors: Andrew McLarnon; Karen P Piper; Oliver C Goodyear; Julie M Arrazi; Premini Mahendra; Mark Cook; Fiona Clark; Guy Pratt; Charles Craddock; Paul A H Moss
Journal: Haematologica Date: 2010-05-11 Impact factor: 9.941

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

1. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

2. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

3. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

5. Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Review 6. Tumor antigens recognized by T lymphocytes.

7. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

8. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

9. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

10. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Review 1. T cell receptor usage in malignant diseases.

2. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Review 3. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

4. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.

5. MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia.

6. Genetic and Environmental Effects on Gene Expression Signatures of Blood Pressure: A Transcriptome-Wide Twin Study.

Review 7. Specific immunotherapy of cancer in elderly patients.

8. Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia.

Review 9. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Review 10. The therapeutic target Hsp90 and cancer hallmarks.